AlphaMeld GmbH provides AI-driven platforms and services to support drug discovery and development. The AlphaMeld platform integrates biological, chemical and clinical data for target identification, indication optimization, drug design, mechanism-of-action analysis, biomarker discovery and clinical-trial strategy and study design, and includes a generative assistant (ChatAlphaMeld) for user interaction.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
AI-, machine-learning- and generative-AI-driven drug discovery and development, including target identification, drug design, prioritisation of target structures and development of transforming therapies.
AlphaMeld Platform
AI-driven platform for connecting scientific, medical, chemical and biological data; supports target and indication selection, biomarker discovery, study strategy and landscape mapping.
ChatAlphaMeld
Generative-AI assistant for interacting with the AlphaMeld platform and its tools; supports stakeholders across the drug discovery and development lifecycle.
Therapeutics development for various disease areas and modalities
Development of therapy candidates for all disease areas and modalities, including small molecules, biologics as well as cell and gene therapies; with a particular focus on obesity research.
Knowledge
No knowledge articles yet
Once AlphaMeld GmbH has claimed this profile, we'll publish editorial articles and case studies here together.